Ligand id: 5082

Name: trastuzumab

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: trastuzumab

Compound class Antibody
Approved drug? Yes (FDA (1998), EMA (2000))
International Nonproprietary Names
INN number INN
7637 trastuzumab
D5v8 | Herceptin® | R-597
Trastuzumab is a humanized IgG1κ monoclonal antibody targeting HER2.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.

NameTrade nameCompanyClinical PhaseIndications
trastuzumab-dkst; MYL-1401OHertraz; Canmab; OgivriMylan and Biocon Approved in India, FDA 2017 (Ogivri)Breast cancer
CT-P6Herzum; CredimaCelltrionApproved in S Korea, pre-registered with the EMABreast cancer
SB3OntruzantSamsung BioepisApproved (EMA 2017)Metastatic breast cancer
trastuzumab-beta; ABP-980 [2] AmgenPh 3 (link to all ABP-980 studies)Breast and gastro/esophageal cancers
HLX02 Shanghai Henlius BiotechPh 3 (NCT03084237)Breast cancer
PF-05280014 PfizerPh 3 (see REFLECTIONS B327-02 trial NCT01989676)Breast cancer
Database Links
Specialist databases
IMGT/mAb-DB 97
Other databases
GtoPdb PubChem SID 178101775
PubChem SID 178101775
Search PubMed clinical trials trastuzumab
Search PubMed titles trastuzumab
Search PubMed titles/abstracts trastuzumab
Wikipedia Trastuzumab